川芎嗪逆转急性白血病多药耐药性初步临床研究  

Principal Clinical Study on Ligustrazine Injection to Counteract the Multi-drug Resistance of Acute Leukemia

作　　者：赵永辰[1] 陈信义[2] 许亚梅[2] 贾玫[2] 

机构地区：[1]河北省职工医学院附属医院,保定071000 [2]北京中医药大学东直门医院

出　　处：《中国中医药信息杂志》2003年第12期10-12,共3页Chinese Journal of Information on Traditional Chinese Medicine

基　　金：高等学校博士点专项基金资助(№.2000002611);教育部高等学校骨干教师资助计划专项基金资助(№.356)

摘　　要：目的:考察川芎嗪注射液作为急性白血病多药耐药逆转剂用于临床的可能性,为临床推广应用提供依据。方法:按急性白血病与多药耐药相关蛋白(MRP)阳性表达标准选择病例,治疗组在化疗同时伍用川芎嗪注射液,并与单纯化疗组对照,按急性白血病临床疗效标准评定临床疗效。结果:川芎嗪可下调MRP阳性表达率、降低骨髓幼稚细胞百分率、提高白血病临床缓解率。结论:川芎嗪注射液可作为低毒的耐药逆转剂用于克服急性白血病(肿瘤)多药耐药。s Objective: To investigate the clinical probability of Ligustrazine injection being used to counteract the multi-drug resistance of acute leukemia, so providing evidence to extend using of clinic. Methods: According to the standard selection method of acute leukemia and positive MRP, the team use the Ligustrazine injection when chemotherapy, and comparing with the method of using the chemotherapy only. They assess the clinical curative effect in term of the clinical curative effect standard of acute leukemia. Results: Ligustrazine may reduce the rate of positive MRP, the percent of the marrow infantilism cell. Conclusion: Ligustrazine injection may act as low- noxious counteract the multi-drug resistance of acute leukemia.

关 键 词：川芎嗪 逆转 急性白血病 多药耐药性 临床研究 

分 类 号：R733.71[医药卫生—肿瘤]